Boehringer Blood Thinner Linked To Heart Attacks: Study

Law360, New York (January 10, 2012, 7:15 PM EST) -- A new study released Monday found that Boehringer Ingelheim GmbH's Pradaxa carries an increased risk of heart attack compared with other anti-coagulants, spurring at least one plaintiffs' firm to put out a feeler for potential clients who took the drug.

The study in the Archives of Internal Medicine examined seven trials with 30,514 participants, finding a “small increased” heart attack risk with dabigatran, the main ingredient in Pradaxa, compared with the blood thinners warfarin or enoxaparin, or a placebo.

Out of 20,000 patients who took dabigatran,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.